Lonza develop, manufacture Intellect’s antibody drug conjugate

Lonza to develop, manufacture Intellect’s antibody drug conjugate

10:00 AM, 27th September 2012
Lonza to develop, manufacture Intellect’s antibody drug conjugate

NEW YORK, US/BASEL, SWITZERLAND: Lonza announced that Intellect Neurosciences awarded the future development and manufacture of the antibody drug conjugate CONJUMAB-A to Lonza, subject to completion of a definitive development and manufacturing agreement.

Lonza will supply the preclinical study material for drug optimization and drug selection for Intellect’s CONJUMAB-A, initially focusing on age-related macular degeneration (AMD) with potential applications for Alzheimer’s disease. Intellect Neurosciences is a biopharmaceutical company engaged in discovery and development of disease-modifying therapeutic agents for the treatment of proteinopathies.

The new programme is expected to include in-vitro and in-vivo studies to evaluate both therapeutic and prophylactic potential in AMD testing different chemical variants manufactured by Lonza. Intellect also plans to work with a number of independent specialized contract research organizations to evaluate the compounds produced by Lonza Chemical Manufacturing in Visp, Switzerland.

Intellect’s programme is led by Dan Shochat, PhD, Intellect Neurosciences’ Consulting Vice President of Development and pioneer in development of antibody drug conjugates for cancer treatments.

“CONJUMAB-A is a first-in-class drug compound intended to address an important unmet need in AMD, which is the leading cause of blindness in people over the age of 55. We anticipate improved efficacy compared to naked amyloid beta antibodies currently in clinical development for AMD. The selection of Lonza as our manufacturer, just under a year since we introduced the platform, represents an important next step in the evolution of Intellect Neurosciences,” said Dr Daniel Chain, Chairman and CEO, Intellect Neurosciences.

“We have already generated a detailed road map for optimization and manufacture of CONJUMAB-A and are excited to be associated with this entirely novel and promising application for antibody-drug conjugates,” said Stefan Stoffel, Head, Chemical Manufacturing, Lonza.

© WOC News



Your Comments (Up to 2000 characters)
Please respect our community and the integrity of its participants. WOC reserves the right to moderate and approve your comment.

Related News

Gevo switches to ethanol production, optimizes isobutanol technology

ENGLEWOOD, US: Gevo is switching its Luverne, MN biorefinery back to ethanol production while it works to optimize isobutanol production rates. The co ...

Read more
Incitec Pivot defers developing ammonium nitrate unit at Newcastle site

VICTORIA, AUSTRALIA: Incitec Pivot Limited (IPL) has suspended its feasibility study on the development of an ammonium nitrate manufacturing complex a ...

Read more
Appeals court lifts ban on rival to DuPont’s Kevlar

WILMINGTON, US: South Korea’s Kolon Industries Inc can continue to make a rival version of DuPont’s Kevlar synthetic fibre used in body ar ...

Read more
AkzoNobel expands Texas site, to meet semiconductor market demand

AMSTERDAM, THE NETHERLANDS: AkzoNobel is to boost capacity at one of its US sites in order to meet increasing demand from the semiconductor industry, ...

Read more
Williams’ new gas processing deal with Canadian Oil Sands producer

TULSA, US: Williams has signed a new long-term gas processing agreement with a producer in the Canadian oil sands. With this, Williams will extract, t ...

Read more
Incitec Pivot starts ammonia production in Moranbah, Australia

VICTORIA, AUSTRALIA: Incitec Pivot Limited (IPL) has achieved a further milestone at its ammonium nitrate complex at Moranbah in Queensland’s Bo ...

Read more
www.worldofchemicals.com uses cookies to ensure that we give you the best experience on our website. By using this site, you agree to our Privacy Policy and our Terms of Use. X